Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Launched by KEYMED BIOSCIENCES CO.LTD · Mar 17, 2021

Keywords

ClinConnect Summary

Subjects will be required to apply moisturizers after ICF signed and continue throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed as AD for at least 12 months before Screening, with below requirements: 1)EASI score ≥16 at Screening and Baseline; 2) IGA score ≥3 (0-5 points scale) at Screening and Baseline; 3) ≥10% BSA of AD involvement at Screening and Baseline; 4) Pruritus NRS average score ≥3 at Baseline.
• • Inadequate response to topical medications.
• Exclusion Criteria:
• • Not enough washing-out period for previous therapy.
• • Concurrent disease/status which may potentially affect the efficacy/safety judgement.
• • Organ dysfunction.
• • pregnancy.
• • Other.